Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome

Neuroscience Letters

Volumn 287, Issue 2, 2000, Pages 109-112

  Durany, Nuria ^a,b   Zöchling, Robert ^c   Boissl, Karl W ^c   Paulus, Werner ^d   Ransmayr, Gerhard ^e   Tatschner, Thomas ^b   Danielczyk, Walter ^f,g   Jellinger, Kurt ^f,g   Deckert, Jürgen ^b   Riederer, Peter ^b  

^a UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Stt Hosp of Neurol and Psychiatry   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF INNSBRUCK   (Austria)

^f LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^g Geriatric Ctr 'Wienerwald' A 1130   (Austria)

Author keywords

4 2 Nicotinic acetylcholine receptors; Nicotine; Parkinson's syndrome; Schizophrenia

Indexed keywords

NICOTINE; NICOTINIC RECEPTOR;

ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR DENSITY; SCHIZOPHRENIA; TISSUE DISTRIBUTION;

AGED; AGED, 80 AND OVER; ALKALOIDS; AZOCINES; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; QUINOLIZINES; RADIOLIGAND ASSAY; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; TRITIUM;

EID: 0343238218     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)01144-7     Document Type: Article

References (21)

1. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry. 150:1993;1856-1861.
2. Aubert I., Araujo D.M., Cecyre D., Robitaille Y., Gauthier S., Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's disease. J. Neurochem. 50:1992;529-541.
3. Bradford M.W. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
4. Dalack G.W., Healy D.J., Meador-Woodruff J.H. Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings. Am. J. Psychiatry. 155:1998;1490-1501.
5. Decina P., Caracci G., Sandik R., Berman W., Mukherjee G., Scapicchio P. Cigarette smoking and neuroleptic-induced parkinsonism. Biol. Psychiatry. 28:1990;502-508.
6. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 41:1992;31-37.
7. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schleyer S., Wolf A.P., Warner D., Zezulkova I., Cilento R. Inhibition of monoamine oxidase B in the brain of smokers. Nature. 379:1996;733-736.
8. Freedman R., Hall M., Adler L.E., Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry. 38:1995;22-33.
9. Gorell M.M., Rybycki B.A., Johnson C.C., Peterson E.L. Smoking and Parkinson's disease. A dose-response relationship. Neurology. 52:1999;115-119.
10. 3H)cytisine binding to human brain membrane preparations. Brain Res. 600:1993;127-133.
11. James J.R., Nordberg A. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behav. Genet. 25:1995;149-159.
12. Lange K.W., Wells F.R., Jenner P., Marsden C.D. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J. Neurochem. 60:1993;197-203.
13. Linert W., Bridge M.H., Huber M., Bjugstad K.B., Grossman S., Arendash G.W. In vitro and in vivo studies investigating possible antitoxidant actions of nicotine: relevance to Parkinson's and Alzheimer's Disease. Biochim. Biophys. Acta. 1454:2000;143-152.
14. Maggio R., Riva M., Vaglini F., Fornai F., Molteni R., Armogida M., Racagni G., Corsini G.U. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J. Neurochem. 71:1998;2439-2446.
15. McPherson G.A. Analysis of radioligand binding experiments. J. Pharmacol. Methods. 14:1985;213-228.
16. Mendez-Alvarez E., Soto-Otero R., Sanchez-Sellero I., Lamas M.L.R. In vitro inhibition of catalase activity by cigarette smoke: relevance for oxidative stress. J. Appl. Toxicol. 18:1998;443-448.
17. Minana M.D., Montoliu C., Llansola M., Grisolia S., Felipo V. Nicotine prevents glutamate-induced proteolysis of the microtubule-associated protein MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neurons. Neuropharmacology. 37:1998;847-857.
18. Morens D.M., Grandinetti A., Reed D., White L.R., Ross G.W. Cigarette smoking and protection from Parkinson's disease. Neurology. 45:1995;1041-1051.
19. Nordberg A., Alafuzoff I., Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 31:1992;103-111.
20. Spieker S., Breit S., Klockgether T., Dichgans J. Tremorlytic activity of budipine in Parkinson's disease. J. Neural. Transm. 56:1999;165-172.
21. Sullivan J.P., Donnelly-Roberts D., Briggs C.A., Anderson D.J., Gopalakrishnan M., Piattoni-Kaplan M., Campbell J.E., McKenna D.G., Molinari E., Hettinger A.-M., Garvey D.S., Wasicak J.T., Holladay M.W., Williams M., Arneric S.P. A-83580 (3-(2(S)-Azetidinylmethoxy)pyridine): in vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand. Neuropharmacology. 35:1996;725-734.